{
  "ticker": "JNJ",
  "target_date": "2025-09-19",
  "actual_date": "2025-09-19",
  "collected_at": "2025-12-08T12:18:10.920269",
  "price": {
    "open": 173.59,
    "high": 176.04,
    "low": 172.24,
    "close": 175.07839965820312,
    "volume": 25621000,
    "change_1d_pct": 1.17,
    "change_7d_pct": 0.23,
    "change_30d_pct": 3.47
  },
  "technicals": {
    "rsi_14": 46.78,
    "sma_20": 176.04,
    "sma_50": 170.53,
    "macd": 1.243,
    "macd_signal": 1.989,
    "macd_histogram": -0.746,
    "bb_upper": 178.35,
    "bb_lower": 173.72,
    "price_vs_sma20_pct": -0.54,
    "price_vs_sma50_pct": 2.67,
    "volume_ratio": 3.1
  },
  "fundamentals": {
    "market_cap": 487388348416,
    "pe_ratio": 19.526545,
    "forward_pe": 19.084433,
    "price_to_book": 6.1400127,
    "price_to_sales": 5.2891335,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.65,
    "pct_from_52w_low": 43.8
  },
  "macro": {
    "spy": {
      "price": 663.7,
      "change_1d_pct": 0.5,
      "change_7d_pct": 1.2
    },
    "vix": {
      "level": 15.45,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.14
    },
    "dollar_index": {
      "level": 97.64
    },
    "gold": {
      "price": 3671.5
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "TREMFYA\u00ae (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen",
      "source": "Yahoo",
      "datetime": 1758320880,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA\u00ae (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). With this approval, TREMFYA\u00ae is the first",
      "url": "https://finnhub.io/api/news?id=3ba8d24d27e2c67686d6716e6fa9be7c9840a7cab514bdee4d129f935931f3ad"
    },
    {
      "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
      "source": "Yahoo",
      "datetime": 1758315770,
      "summary": "Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and",
      "url": "https://finnhub.io/api/news?id=ccaec67fa21b9adcb24ec0acf9de8ee6c6248edb7bed7f983e333b3b6e90cb6c"
    },
    {
      "headline": "Can Regeneron Change The Paradigm In Multiple Myeloma \u2014 And Undercut J&J?",
      "source": "Yahoo",
      "datetime": 1758305734,
      "summary": "Regeneron unveiled what it calls \"paradigm-shifting\" test results for a drug that could prevent patients from developing multiple myeloma.",
      "url": "https://finnhub.io/api/news?id=dcf977a2bc6e2599d37a000455caf112778cb173385a46670d73969b3b8ad19f"
    },
    {
      "headline": "Johnson & Johnson Gets Approval for Subcutaneous Induction Option for Ulcerative Colitis",
      "source": "MarketWatch",
      "datetime": 1758305580,
      "summary": "Johnson & Johnson Gets Approval for Subcutaneous Induction Option for Ulcerative Colitis",
      "url": "https://finnhub.io/api/news?id=c8bcc2663f793c509e8f2db804a18b7142d7bd823bae1f04e9fa94c6aaa751f5"
    },
    {
      "headline": "J&J\u2019s newly diagnosed multiple myeloma induction combo elicits 100% OR",
      "source": "Yahoo",
      "datetime": 1758301591,
      "summary": "In MRD-evaluable patients, 100% achieved MRD negativity after six cycles of treatment.",
      "url": "https://finnhub.io/api/news?id=4625a55f71c2524ea4c3499685f710a14a4941b2777f900af20831dad4aebb89"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627206.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000192/xslF345X05/wk-form4_1757627206.xml"
    },
    {
      "form": "8-K",
      "date": "2025-09-09",
      "description": "jnj-20250908.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000190/jnj-20250908.htm"
    },
    {
      "form": "4",
      "date": "2025-09-05",
      "description": "xslF345X05/wk-form4_1757109644.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000186/xslF345X05/wk-form4_1757109644.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}